Search Results - "Gerbing, R"

A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group by Eidenschink Brodersen, L, Alonzo, T A, Menssen, A J, Gerbing, R B, Pardo, L, Voigt, A P, Kahwash, S B, Hirsch, B, Raimondi, S, Gamis, A S, Meshinchi, S, Loken, M R

Get full text

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study by Ho, P A, Alonzo, T A, Kopecky, K J, Miller, K L, Kuhn, J, Zeng, R, Gerbing, R B, Raimondi, S C, Hirsch, B A, Oehler, V, Hurwitz, C A, Franklin, J L, Gamis, A S, Petersdorf, S H, Anderson, J E, Reaman, G H, Baker, L H, Willman, C L, Bernstein, I D, Radich, J P, Appelbaum, F R, Stirewalt, D L, Meshinchi, S

“…Recent whole-genome sequencing efforts led to the identification of IDH1 R132 mutations in acute myeloid leukemia (AML) patients. We studied the prevalence and…”
Get full text

Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia by Narayanan, P., Man, T.-K., Gerbing, R. B., Ries, R., Stevens, A. M., Wang, Y.-C., Long, X., Gamis, A. S., Cooper, T., Meshinchi, S., Alonzo, T. A., Redell, M. S.

“…The relapse rate for children with acute myeloid leukemia is nearly 40% despite aggressive chemotherapy and often stem cell transplant. We sought to understand…”
Get full text

Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid by Matthay, Katherine K, Villablanca, Judith G, Seeger, Robert C, Stram, Daniel O, Harris, Richard E, Ramsay, Norma K, Swift, Patrick, Shimada, Hiroyuki, Black, C. Thomas, Brodeur, Garrett M, Gerbing, Robert B, Reynolds, C. Patrick

“…Neuroblastoma, the most common extracranial solid tumor of childhood, has a long-term survival rate of only 15 percent. 1 At diagnosis the defining…”
Get full text

Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 by Smith, F O, Alonzo, T A, Gerbing, R B, Woods, W G, Arceci, R J

“…The Children's Cancer Group (CCG) conducted three Phase III prospective clinical trials for children with de novo acute myeloid leukemia between the years 1979…”
Get full text

PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group by LOH, M. L, REYNOLDS, M. G, VATTIKUTI, S, GERBING, R. B, ALONZO, T. A, CARLSON, E, CHENG, J. W, LEE, C. M, LANGE, B. J, MESHINCHI, S

“…The PTPN11 gene encodes SHP-2, a nonreceptor protein tyrosine phosphatase that relays signals from activated growth factor receptors to p21(ras) (Ras) and…”
Get full text

The International Neuroblastoma Pathology Classification (the Shimada system) by Shimada, Hiroyuki, Ambros, Inge M., Dehner, Louis P., Hata, Jun‐ichi, Joshi, Vijay V., Roald, Borghild, Stram, Daniel O., Gerbing, Robert B., Lukens, John N., Matthay, Katherine K., Castleberry, Robert P.

“…BACKGROUND The International Neuroblastoma Pathology Committee, which is comprised of six member pathologists, was convened with the objective of proposing a…”
Get full text

Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group by Berman, J N, Gerbing, R B, Alonzo, T A, Ho, P A, Miller, K, Hurwitz, C, Heerema, N A, Hirsch, B, Raimondi, S C, Lange, B, Franklin, J L, Gamis, A, Meshinchi, S

Get full text

Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group by Aplenc, R., Fisher, B. T., Huang, Y. S., Li, Y., Alonzo, T. A., Gerbing, R. B., Hall, M., Bertoch, D., Keren, R., Seif, A. E., Sung, L., Adamson, P. C., Gamis, A.

“…ABSTRACT Purpose The National Cancer Institute–funded cooperative oncology group trials have improved overall survival for children with cancer from 10% to 85%…”
Get full text

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children’s Oncology Group by Kutny, M A, Alonzo, T A, Gamazon, E R, Gerbing, R B, Geraghty, D, Lange, B, Heerema, N A, Sung, L, Aplenc, R, Franklin, J, Raimondi, S C, Hirsch, B A, Konkashbaev, A, Cox, N J, Onel, K, Gamis, A S, Meshinchi, S

Get full text

DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group by Bhatla, D, Gerbing, R B, Alonzo, T A, Mehta, P A, Deal, K, Elliott, J, Meshinchi, S, Geiger, H, Perentesis, J P, Lange, B J, Davies, S M

“…Polymorphisms of DNA repair genes RAD51 and XRCC3 increase susceptibility to acute myeloid leukemia (AML) in adults, an effect enhanced by deletion of the…”
Get full text

Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children’s Cancer Group Study by NICKERSON, H. J, MATTHAY, K. K, LUKENS, J, SEEGER, R. C, BRODEUR, G. M, SHIMADA, H, PEREZ, C, ATKINSON, J. B, SELCH, M, GERBING, R. B, STRAM, D. O

“…Stage IV-S neuroblastoma is a metastatic disease associated with spontaneous regression and good survival, but 10% to 20% of infants die from early…”
Get full text

Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children’s Cancer Group Study by SEEGER, Robert C, REYNOLDS, C. Patrick, GALLEGO, Richard, STRAM, Daniel O, GERBING, Robert B, MATTHAY, Katherine K

“…This study investigated the prognostic value of quantifying tumor cells in bone marrow and blood by immunocytology in children with high-risk, metastatic…”
Get full text

Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era by ALONZO, T. A, WELLS, R. J, WOODS, W. G, LANGE, B, GERBING, R. B, BUXTON, A. B, NEUDORF, S, SANDERS, J, SMITH, F. O, FEIG, S. A

“…We reviewed consolidation therapy results and analyzed postremission outcomes for 1464 children less than 21 years old at diagnosis in five consecutive…”
Get full text

Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study by SCHMIDT, M. L, LUKENS, J. N, SEEGER, R. C, BRODEUR, G. M, SHIMADA, H, GERBING, R. B, STRAM, D. O, PEREZ, C, HAASE, G. M, MATTHAY, K. K

“…A prospective Children's Cancer Group study, CCG-3881, has been completed to determine if a more accurate prediction of prognosis by biologic features can…”
Get full text

Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children’s Cancer Group Study by PEREZ, C. A, MATTHAY, K. K, ATKINSON, J. B, SEEGER, R. C, SHIMADA, H, HAASE, G. M, STRAM, D. O, GERBING, R. B, LUKENS, J. N

“…To determine prospectively whether surgery alone is sufficient therapy for Evans stages I and II neuroblastoma and to define biologic and clinical features…”
Get full text

High-Dose Melphalan, Etoposide, Total-Body Irradiation, and Autologous Stem-Cell Reconstitution as Consolidation Therapy for High-Risk Ewing’s Sarcoma Does Not Improve Prognosis by MEYERS, Paul A, KRAILO, Mark D, HERZOG, Cynthia E, LINDSLEY, Karen L, LIU-MARES, Wen, NACHMAN, James B, SIEGER, Lance, WADMAN, Jean, GORLICK, Richard G, LADANYI, Marc, CHAN, Ka-Wah, SAILER, Scott L, DICKMAN, Paul S, BAKER, David L, DAVIS, Jeffrey H, GERBING, Robert B, GROVAS, Alfred

“…To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would…”
Get full text

Revision of the International Neuroblastoma Pathology classification: Confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular by PEUCHMAUR, Michel, D'AMORE, Emanuele S. G, SHIMADA, Hiroyuki, JOSHI, Vijay V, HATA, Jun-Ichi, ROALD, Borghild, DEHNER, Louis P, GERBING, Robert B, STRAM, Daniel, LUKENS, John N, MATTHAY, Katherine K

“…Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original…”
Get full text

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study by MARIS, J. M, WEISS, M. J, MATTHAY, K. K, SEEGER, R. C, BRODEUR, G. M, CHUN GUO, GERBING, R. B, STRAM, D. O, WHITE, P. S, HOGARTY, M. D, SULMAN, E. P, THOMPSON, P. M, LUKENS, J. N

“…To determine the independent prognostic significance of 1p36 loss of heterozygosity (LOH) in a representative group of neuroblastoma patients. Diagnostic tumor…”
Get full text

International Neuroblastoma Pathology Classification for prognostic evaluation of patients with peripheral neuroblastic tumors : A report from the Children's Cancer Group by SHIMADA, Hiroyuki, UMEHARA, Shunsuke, MONOBE, Yasumasa, HACHITANDA, Yoichi, NAKAGAWA, Atsuko, GOTO, Shoko, GERBING, Robert B, STRAM, Daniel O, LUKENS, John N, MATTHAY, Katherine K

“…The International Neuroblastoma Pathology Classification was established in 1999 for the prognostic evaluation of patients with neuroblastic tumors (NTs)…”
Get full text